Collegium Pharmaceutical (NASDAQ:COLL) – Investment analysts at Jefferies Group issued their Q2 2018 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a report issued on Thursday, according to Zacks Investment Research. Jefferies Group analyst D. Steinberg expects that the specialty pharmaceutical company will post earnings of ($0.12) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $32.00 target price on the stock. Jefferies Group also issued estimates for Collegium Pharmaceutical’s Q3 2018 earnings at ($0.05) EPS, Q4 2018 earnings at ($0.03) EPS and FY2022 earnings at $2.75 EPS.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.02. The firm had revenue of $10.79 million for the quarter, compared to the consensus estimate of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. Collegium Pharmaceutical’s revenue was up 728.4% compared to the same quarter last year.
A number of other research analysts also recently issued reports on the company. BidaskClub raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 28th. TheStreet raised Collegium Pharmaceutical from a “d+” rating to a “c” rating in a research note on Wednesday, March 7th. William Blair reissued an “outperform” rating on shares of Collegium Pharmaceutical in a research note on Thursday, March 8th. HC Wainwright boosted their price objective on Collegium Pharmaceutical from $21.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Finally, Piper Jaffray set a $33.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Monday, February 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $29.17.
COLL traded down $1.91 during midday trading on Friday, hitting $23.64. 394,769 shares of the company were exchanged, compared to its average volume of 602,211. The company has a market capitalization of $842.99, a PE ratio of -9.57 and a beta of 0.76. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $29.90.
In related news, Chairman Michael Thomas Heffernan sold 20,000 shares of the business’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $22.50, for a total value of $450,000.00. Following the completion of the sale, the chairman now directly owns 538,987 shares of the company’s stock, valued at approximately $12,127,207.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alison B. Fleming sold 6,928 shares of the business’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total value of $132,116.96. Following the completion of the sale, the insider now directly owns 32,651 shares of the company’s stock, valued at $622,654.57. The disclosure for this sale can be found here. Insiders sold a total of 46,928 shares of company stock worth $1,082,317 over the last three months. 25.76% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Benjamin F. Edwards & Company Inc. increased its position in Collegium Pharmaceutical by 87.5% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 3,500 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $176,000. Voya Investment Management LLC bought a new stake in Collegium Pharmaceutical during the 2nd quarter worth approximately $125,000. Nationwide Fund Advisors increased its holdings in Collegium Pharmaceutical by 27.8% during the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after purchasing an additional 2,802 shares in the last quarter. Finally, Monarch Partners Asset Management LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $264,000. 86.39% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://theenterpriseleader.com/2018/04/02/jefferies-group-comments-on-collegium-pharmaceutical-incs-q2-2018-earnings-nasdaqcoll.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.